The 35th CINP World Congress of Neuropsychopharmacology

セッション情報

[CINP2024] Poster Session

CINP2024 » Poster Session

Schizophrenia 2 -Preclinical

2024年5月24日(金) 17:30 〜 18:30 CINP Poster Session Hall (Lobby Gallery)

*Akira Yoshimi1,2, Susumu Y Imanishi3, Tomoya Oguchi1, Shinji Kitagaki4, Norio Ozaki5, Yukihiro Noda1,2 (1. Division of Clinical Sciences and Neuropsychopharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 2. Clinical OMICs and Translation Research Center, Meijo University, Nagoya, Japan, 3. Laboratory of Analytical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 4. Laboratory of Medicinal Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 5. Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan)

*Yosefu Arime1, Yoshito Saitoh1, Yasuo Uchida2, Mikiko Ishikawa1, Chikako Kamiyoshihara1, Kazuki Fujii3,4,5, Keizo Takao3,4,5, Noriaki Ohkawa1 (1. Division for Memory and Cognitive Function, Research Center for Advanced Medical Science, Comprehensive Research Facilities for Advanced Medical Science, Dokkyo Medical University, 2. Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, 3. Department of Behavioral Physiology, Faculty of Medicine, University of Toyama, 4. Life Science Research Center, University of Toyama, 5. Research Center for Idling Brain Science, University of Toyama)

*Shunya Kawai1, Akira Yoshimi1,2, Ayaka Kato1, Mizuki Uchida1, Shinji Kitagaki3, Norio Ozaki4, Yukihiro Noda1,2 (1. Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, Faculty and Graduate School of Pharmacy, Nagoya, Japan, 2. Clinical OMICs and Translation Research Center, Meijo University, Nagoya, Japan, 3. Laboratory of Medicinal Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 4. Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan)

*Greg Stewart1,2, Yao Lu1, Sheng Yu Ang1,2, Daisy Spark2,3, Juulke Castelijn2,3, Trang Pham2,4, Michelle Camerino2,4, Monica Langiu1, Natalie Diepenhorst1, Clotilde Mannoury La Cour5, Leonid Churilov6, Jess Nithianantharajah2,3, Chris Langmead1,2 (1. Drug Discovery Biology, Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia, 2. Phrenix Therapeutics, Parkville, Victoria, Australia, 3. The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, 4. Australian Translational Medicinal Chemistry Facility, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia, 5. Les Laboratoires Servier, Suresnes, Paris, France, 6. Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia)

*Hana Walaska1, Michal Maryska1,2, Lucie Svobodova1, Wim Dehaen3, Martin Kuchar1,2 (1. Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, Faculty of Food and Biochemical Technology, UCT Prague, Technická 5, 16628 Prague, Czech Republic, 2. National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic, 3. CZ-OPENSCREEN: National Infrastructure for Chemical Biology, Department of Informatics and Chemistry, Faculty of Chemical Technology, UCT Prague, Technická 5, 16628 Prague, Czech Republic)

*Ami Ono1, Daichi Koan1, Satoshi Asano1, Tatsunori Miyaoka2, Lu Chen2, Shinsaku Nakagawa2, Atsuko Hayata-Takano3,4, Takanobu Nakazawa5, Akihiro Harada6, Hitoshi Hashimoto2,4,6, James A Waschek7, Kotaro Tanimoto1, Yukio Ago1 (1. Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan, 2. Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, 3. Graduate School of Dentistry, Osaka University, Osaka, Japan, 4. United Graduate School of Child Development, Osaka University, Osaka, Japan, 5. Department of Bioscience, Tokyo University of Agriculture, Tokyo, Japan, 6. Graduate School of Medicine, Osaka University, Osaka, Japan, 7. Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, CA, USA)

*Fumika Ando1, Akihiro Mouri1,2, Kazuo Kunisawa1, Shuhei Yamagishi1, Yuji Komaki3, Kazuki Takano4, Toshitaka Nabeshima2,5 (1. Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Sciences, Aichi, Japan., 2. Japanese Drug Organization of Appropriate Use and Research (J-DO), Aichi, Japan., 3. Central Institute for Experimental Animals (CIEA), 4. Department of Molecular Imaging, Fujita Health University Graduate School of Health Sciences., 5. Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Science, Aichi, Japan.)

×

認証

×

要旨・抄録、PDFの閲覧には参加者用アカウントでのログインが必要です。参加者ログイン後に閲覧・ダウンロードできます。
» 参加者用ログイン